There is no doubt that schizophrenia has a significant genetic component and a number of candidate genes have been identified for this debilitating disorder. Of note, several of these are implicated in cognition. Cognitive deficits constitute core symptoms of schizophrenia, and while current antipsychotic treatment strategies aim to help psychosis-related symptomatology, the cognitive symptom domain is largely inadequately treated. A number of other pharmacological approaches (e.g. using drugs that target specific neurotransmitter systems) have also been attempted for the amelioration of cognitive deficits in this population; however, these too have had limited success so far. Psychological interventions appear promising, though there has been speculation regarding whether or not these produce long-term functional improvements. Pharmacogenetic studies of the cognitive effects of currently available antipsychotics, although in relatively early stages, suggest that the treatment of cognitive deficits in schizophrenia may be advanced by focusing on genetic variants associated with specific cognitive dysfunctions in the general population and using this to match the most relevant pharmacological and/or psychological interventions with the genetic and cognitive profiles of the target population. Such a strategy would encourage bottom-up advances in drug development and provide a platform for individualised treatment of cognitive deficits in schizophrenia.
Abi-DarghamAMawlawiOLombardoI. (2002) Prefrontal dopamine D1 receptors and working memory in schizophrenia. J Neurosci22: 3708–3719.
2.
AdcockRADaleCFisherM. (2009) When top-down meets bottom-up: Auditory training enhances verbal memory in schizophrenia. Schizophr Bull35: 1132–1141.
3.
AddingtonAMRapoportJL (2009) The genetics of childhood onset schizophrenia: When madness strikes the prepubescent. Curr Psychiatry Rep11: 156–161.
4.
AddingtonAMRapoportJL (2011) Annual research review: impact of advances in genetics in understanding developmental psychopathology. J Child Psychol PsychiatryNov8. doi: 10.1111/j.1469-7610.2011.02478.x10.1111/j.1469-7610.2011.02478.x. [Epub ahead of print].
5.
AddingtonJAddingtonD (1999) Neurocognitive and social functioning in schizophrenia. Schizophr Bull25: 173–182.
6.
AddingtonJMcClearyLMunroe-BlumH (1998) Relationship between cognitive and social dysfunction in schizophrenia. Schizophr Res34: 59–66
7.
AghotorJPfuellerUMoritzS. (2010) Metacognitive training for patients with schizophrenia (MCT): Feasibility and preliminary evidence for its efficacy. J Behav Ther Exp Psychiatry41: 207–211.
8.
AlbusMHubmannWSchererJ. (2002) A prospective 2-year follow-up study of neurocognitive functioning in patients with first-episode schizophrenia. Eur Arch Psychiatry Clin Neurosci252: 262–267.
9.
AlemanAHijmanRde HaanEH. (1999) Memory impairment in schizophrenia: A meta-analysis. Am J Psychiatry156: 1358–1366.
10.
AlemanAKahnRSSeltenJP (2003) Sex differences in the risk of schizophrenia: Evidence from meta-analysis. Arch Gen Psychiatry60: 565–571.
11.
AllenNCBagadeSMcQueenMB. (2008) Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: The SzGene database. Nat Genet40: 827–834.
12.
AllmanJMTetreaultNAHakeemAY. (2010) The von Economo neurons in frontoinsular and anterior cingulate cortex in great apes and humans. Brain Struct Funct214: 495–517.
ApudJAMattayVChenJ. (2007) Tolcapone improves cognition and cortical information processing in normal human subjects. Neuropsychopharmacology32: 1011–1020.
15.
ArntJSkarsfeldtT (1998) Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology18: 63–101.
16.
BaigBJWhalleyHCHallJ. (2010) Functional magnetic resonance imaging of BDNF val66met polymorphism in unmedicated subjects at high genetic risk of schizophrenia performing a verbal memory task. Psychiatry Res183: 195–201.
17.
BaluDTCoyleJT (2011) Neuroplasticity signaling pathways linked to the pathophysiology of schizophrenia. Neurosci Biobehav Rev. 35: 848–870.
18.
BasuAPereiraJAitchisonKJ (2007) The pharmacological management of schizophrenia. In: SteinGWilkinsonG (eds) College Seminar Series in General Adult Psychiatry. 2nd ed.London: Gaskell (Royal College of Psychiatrists) UK.
BermanKFZecRFWeinbergerDR (1986) Physiologic dysfunction of dorsolateral prefrontal cortex in schizophrenia. II. Role of neuroleptic treatment, attention, and mental effort. Arch Gen Psychiatry43: 126–135.
21.
BertolinoACaforioGBlasiG. (2004) Interaction of COMT (Val(108/158)Met) genotype and olanzapine treatment on prefrontal cortical function in patients with schizophrenia. Am J Psychiatry161: 1798–1805.
BilderRMGoldmanRSRobinsonD. (2000) Neuropsychology of first-episode schizophrenia: Initial characterization and clinical correlates. Am J Psychiatry157: 549–559.
24.
BilderRMVolavkaJCzoborP. (2002) Neurocognitive correlates of the COMT Val(158)Met polymorphism in chronic schizophrenia. Biol Psychiatry52: 701–707.
25.
BishopJREllingrodVLMolineJ. (2005) Association between the polymorphic GRM3 gene and negative symptom improvement during olanzapine treatment. Schizophr Res77: 253–260.
26.
BoksMPRietkerkTVandeBeekMH. (2007) Reviewing the role of the genes G72 and DAAO in glutamate neurotransmission in schizophrenia. Eur Neuropsychopharmacol17: 567–572.
27.
BosiaMAnselmettiSPirovanoA. (2010) HTTLPR functional polymorphism in schizophrenia: Executive functions vs. sustained attention dissociation. Prog Neuropsychopharmacol Biol Psychiatry34: 81–85.
28.
BottoLDMayKFernhoffPM. (2003) A population-based study of the 22q11.2 deletion: Phenotype, incidence, and contribution to major birth defects in the population. Pediatrics112: 101–107.
29.
BrayNJPreeceAWilliamsNM. (2005) Haplotypes at the dystrobrevin binding protein 1 (DTNBP1) gene locus mediate risk for schizophrenia through reduced DTNBP1 expression. Hum Mol Genet14: 1947–1954.
30.
BrysonGBellMD (2003) Initial and final work performance in schizophrenia: Cognitive and symptom predictors. J Nerv Ment Dis191: 87–92.
31.
BuchananRW (2006) Important steps in the development of cognitive-enhancing drugs in schizophrenia. Am J Psychiatry163: 1867–1869.
32.
BuchananRWSummerfeltATekC. (2003) An open-labeled trial of adjunctive donepezil for cognitive impairments in patients with schizophrenia. Schizophr Res59: 29–33.
33.
BuchananRWFreedmanRJavittDC. (2007a) Recent advances in the development of novel pharmacological agents for the treatment of cognitive impairments in schizophrenia. Schizophr Bull33: 1120–1130.
34.
BuchananRWConleyRRDickinsonD. (2007b) Galantamine for the treatment of cognitive impairments in people with schizophrenia. Am J Psychiatry165: 82–89.
35.
BuchananRWConleyRRDickinsonD. (2008) Galantamine for the treatment of cognitive impairments in people with schizophrenia. Am J Psychiatry165: 82–99.
36.
BurdickKELenczTFunkeB. (2006) Genetic variation in DTNBP1 influences general cognitive ability. Hum Mol Genet15: 1563-1568.
BusattoGFKerwinRW (1997) Perspectives on the role of serotonergic mechanisms in the pharmacology of schizophrenia. J Psychopharmacol11: 3–12.
39.
CannonMCaspiAMoffittTE. (2002) Evidence for early-childhood, pan-developmental impairment specific to schizophreniform disorder: results from a longitudinal birth cohort. Arch Gen Psychiatry59: 449–456.
40.
CardnoAGGottesmanII (2000) Twin studies of schizophrenia: From bow-and-arrow concordances to star wars Mx and functional genomics. Am J Med Genet97: 12–17.
41.
CarlssonMCarlssonA (1990) Schizophrenia: a subcortical neurotransmitter imbalance syndrome?Schizophr Bull16: 425–432.
42.
CarpenterWTJr (2004) Clinical constructs and therapeutic discovery. Schizophr Res72: 69–73.
43.
CassensGInglisAKAppelbaumPS. (1990) Neuroleptics: Effects on neuropsychological function in chronic schizophrenic patients. Schizophr Bull16: 477–499.
44.
ChumakovIBlumenfeldMGuerassimenkoO. (2006) Genetic and physiological data implicating the new human gene G72 and the gene for D-amino acid oxidase in schizophrenia. Proc Natl Acad Sci U S A99: 13675–13680.
45.
CincottaSLYorekMSMoschakTM. (2008) Selective nicotinic acetylcholine receptor agonists: potential therapies for neuropsychiatric disorders with cognitive dysfunction. Curr Opin Investig Drugs9: 47–56.
46.
ConwayJL (2009) Exogenous nicotine normalises sensory gating in schizophrenia; therapeutic implications. Med Hypotheses73: 259–62.
47.
CoyleJTTsaiGGoffDC (2002) Ionotropic glutamate receptors as therapeutic targets in schizophrenia. Curr Drug Targets CNS Neurol Disord1: 183–189.
48.
DavidASMalmbergABrandtL. (1997) IQ and risk for schizophrenia: A population-based cohort study. Psychol Med27: 1311–1323.
49.
DeckerMWMcGaughJL (1991) The role of interactions between the cholinergic system and other neuromodulatory systems in learning and memory. Synapse7: 151–168.
50.
DempsterELToulopoulouTMcDonaldC. (2006) Episodic memory performance predicted by the 2bp deletion in exon 6 of the ‘alpha 7-like’ nicotinic receptor subunit gene. Am J Psychiatry163: 1832–1834.
51.
Detera-WadleighSDMcMahonFJ (2006) G72/G30 in schizophrenia and bipolar disorder: Review and meta-analysis. Biol Psychiatry60: 106–114.
52.
DickinsonDHarveyPD (2009) Systemic hypotheses for generalized cognitive deficits in schizophrenia: a new take on an old problem. Schizophr Bull35: 403–414.
53.
DickinsonDIannoneVNWilkCM. (2004) General and specific cognitive deficits in schizophrenia. Biol Psychiatry55: 826–833.
54.
DonohoeGMorrisDWDe SanctisP. (2008) Early visual processing deficits in dysbindin-associated schizophrenia. Biol Psychiatry63: 484–489.
55.
DonohoeGFrodlTMorrisD. (2010) Reduced occipital and prefrontal brain volumes in dysbindin-associated schizophrenia. Neuropsychopharmacology35: 368–373.
56.
DyerMAFreudenreichOCulhaneMA. (2008) High-dose galantamine augmentation inferior to placebo on attention, inhibitory control and working memory performance in nonsmokers with schizophrenia. Schizophr Res102: 88–95.
57.
EganMFGoldbergTEKolachanaBS. (2001) Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia. Proc Natl Acad Sci U S A98: 6917–6922.
58.
EganMFKojimaMCallicottJH. (2003) The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell112: 257–269.
59.
EganMFStraubREGoldbergTE. (2004) Variation in GRM3 affects cognition, prefrontal glutamate, and risk for schizophrenia. Proc Natl Acad Sci U S A101: 12604–12609.
60.
ElliottRSahakianBJ (1995) The neuropsychology of schizophrenia: Relations with clinical and neurobiological dimensions. Psychol Med25: 581–594
61.
ElvevagBGoldbergTE (2000) Cognitive impairment in schizophrenia is the core of the disorder. Crit Rev Neurobiol14: 1–21.
62.
EttingerUKumariVZachariahE. (2003) Effects of procyclidine on eye movements in schizophrenia. Neuropsychopharmacology28: 2199–2208.
63.
FagerlundBSøholmBFink-JensenA. (2007) Effects of donepezil adjunctive treatment to ziprasidone on cognitive deficits in schizophrenia: A double-blind, placebo-controlled study. Clin Neuropharmacol30: 3–12.
64.
FalgatterAJHerrmannMJHohoffC. (2006) DTNBP1 (dysbindin) gene variants modulate prefrontal brain function in healthy individuals. Neuropsychopharmacology31: 2002–2010.
65.
FalgatterAJEhlisACHerrmannMJ. (2010) DTNBP1 (dysbindin) gene variants modulate prefrontal brain function in schizophrenic patients – support for the glutamate hypothesis of schizophrenias. Genes Brain Behav9: 489–497.
66.
FanJBZhangCSGuNF. (2005) Catechol-O-methyltransferase gene Val/Met functional polymorphism and risk of schizophrenia: A large-scale association study plus meta-analysis. Biol Psychiatry57: 139–144.
67.
FijalBAKinonBJKapurS. (2009) Candidate-gene association analysis of response to risperidone in African-American and white patients with schizophrenia. Pharmacogenomics J9: 311–318.
68.
FioravantiMCarloneOVitaleB. (2005) A meta-analysis of cognitive deficits in adults with a diagnosis of schizophrenia. Neuropsychol Rev15: 73–95.
69.
FisherMHollandCMerzenichMM. (2009a) Using neuroplasticity-based auditory training to improve verbal memory in schizophrenia. Am J Psychiatry166: 805–811.
70.
FisherMHollandCSubramaniamK. (2009b) Neuroplasticity-based cognitive training in schizophrenia: An interim report on the effects 6 months later. Schizophr Bull36: 869–879.
71.
FrazierJAMcClellanJFindlingRL. (2007) Treatment of early-onset schizophrenia spectrum disorders (TEOSS): Demographic and clinical characteristics. J Am Acad Child Adolesc Psychiatry46: 979–988.
72.
FreedmanROlincyABuchananRW. (2008) Initial hase 2 trial of a nicotinic agonist in schizophrenia. Am J Psychiatry165: 1040–1047.
73.
FreudenreichOHerzLDeckersbachT. (2005) Added donepezil for stable schizophrenia: A double-blind, placebo-controlled trial. Psychopharmacology181: 358–363.
74.
FriedmanJI (2004) Cholinergic targets for cognitive enhancement in schizophrenia: Focus on cholinesterase inhibitors and muscarinic agonists. Psychopharmacology174: 45–53.
75.
FriedmanJIAdlerDNDavisKL (1999) The role of norepinephrine in the pathophysiology of cognitive disorders: Potential applications to the treatment of cognitive dysfunction in schizophrenia and Alzheimer’s disease. Biol Psychiatry46: 1243–1252.
76.
FriedmanJIAdlerDNTemporiniHD. (2001) Guanfacine treatment of cognitive impairment in schizophrenia. Neuropsychopharmacology25: 402–409.
77.
FriedmanJIAdlerDNHowanitzE. (2002) A double-blind placebo-controlled trial of donepezil adjunctive treatment to risperidone for the cognitive impairment of schizophrenia. Biol Psychiatry51: 349–357.
78.
FriedmanJICarpenterDLuJ. (2008a) A pilot study of adjunctive atomoxetine treatment to second-generation antipsychotics for cognitive impairment in schizophrenia. J Clin Psychopharmacol28: 59–63.
79.
FriedmanJIVrijenhoekTMarkxS. (2008b) CNTNAP2 gene dosage variation is associated with schizophrenia and epilepsy. Mol Psychiatry13: 261–266.
80.
FunkeBFinnCTPlocikAM. (2004) Association of the DTNBP1 locus with schizophrenia in a U.S. population. Am J Hum Genet75: 891–898.
81.
GeorgeMSMolnarCEGreneskoEL. (2007) A single 20 mg dose of dihydrexidine (DAR-0100), a full dopamine D1 agonist, is safe and tolerated in patients with schizophrenia. Schizophr Res93: 42–50
82.
GladsjoJAMcAdamsLAPalmerBW. (2004) A six-factor model of cognition in schizophrenia and related psychotic disorders: relationships with clinical symptoms and functional capacity. Schizophr Bull30: 739–754.
83.
GlessnerJTReillyMRKimCE. (2010) Strong synaptic transmission impact copy number variations in schizophrenia. Proc Natl Acad Sci U S A207: 10584–10589.
84.
GoffDCCoyleJT (2001) The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am J Psychiatry158: 1367–1377.
85.
GoffDCLeahyLBermanI. (2001) A placebo-controlled pilot study of the ampakine CX516 added to clozapine in schizophrenia. J Clin Psychopharmacol21: 484–487.
86.
GoffDCHerzLPoseverT. (2005) A six-month, placebo-controlled trial of D-cycloserine co-administered with conventional antipsychotics in schizophrenia patients. Psychopharmacology179: 144–150
87.
GoffDCKeefeRSECitromeL. (2007) Lamotrigine as add-on therapy in schizophrenia results of 2 placebo-controlled trials. J Clin Psychopharmacol27: 582–589.
88.
GoffDCLambertiJSLeonAC. (2008) A placebo-controlled add-on trial of the ampakine, CX516, for cognitive deficits in schizophrenia. Neuropsychopharmacology33: 465–472.
89.
GogtayNVyasNSTestaR. (2011) Age of onset of schizophrenia: perspectives from structural neuroimaging studies. Schizophr Bull37: 504–513.
90.
GoldJM (2004) Cognitive deficits as treatment targets in schizophrenia. Schizophr Res72: 21–28.
91.
GoldbergTEStraubRECallicottJH. (2006) The G72/G30 gene complex and cognitive abnormalities in schizophrenia. Neuropsychopharmacology31: 2022–2032.
92.
Goldman-RakicPSSelemonLD (1997) Functional and anatomical aspects of prefrontal pathology in schizophrenia. Schizophr Bull23: 437–458.
93.
González-BlanchCCrespo-FacorroBAlvarez-JiménezM. (2008) Lack of association between clinical and cognitive change in first-episode psychosis: The first 6 weeks of treatment. Can J Psychiatry53: 839–847.
94.
GreenMF (1996) What are the functional consequences of neurocognitive deficits in schizophrenia?Am J Psychiatry153: 321–330.
95.
GreenMF (2006) Cognitive impairment and functional outcome in schizophrenia and bipolar disorder. J Clin Psychiatry 67(Suppl. 9): 3–8.
96.
GreenMFKernRSBraffDL. (2000). Neurocognitive deficits and functional outcome in schizophrenia: Are we measuring the ‘right stuff’?Schizophr Bull26: 119–136.
97.
GreenMFKernRSHeatonRK (2004) Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS. Schizophr Res72: 41–51.
98.
HajósMRogersBN (2010) Targeting alpha7 nicotinic acetylcholine receptors in the treatment of schizophrenia. Curr Pharm Des16: 538–554.
99.
HallHSedvallGMagnussonO. (1994) Distribution of D1- and D2-dopamine receptors, and dopamine and its metabolites in the human brain. Neuropsychopharmacology11: 245–256.
100.
HallmayerJFKalaydjievaLBadcockJ. (2005) Genetic evidence for a distinct subtype of schizophrenia characterized by pervasive cognitive deficit. Am J Hum Genet77: 468–476.
101.
HamidovicADlugosAPalmerAA. (2010) Catechol-O-methyltransferase val158met genotype modulates sustained attention in both the drug-free state and in response to amphetamine. Psychiatr Genet20: 85–92.
102.
HarrisonPJLyonLSartoriusLJ. (2008) The group II metabotropic glutamate receptor 3 (mGluR3, mGlu3, GRM3): expression, function and involvement in schizophrenia. J Psychopharmacol22: 308–322.
103.
HarveyPDKeefeRS (2001) Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. Am J Psychiatry158: 176–184.
104.
HawkinsKAKeefeRSChristensenBK. (2008) Neuropsychological course in the prodrome and first episode of psychosis: Findings from the PRIME North America Double Blind Treatment Study. Schizophr Res105: 1–9.
105.
HeinrichsRWZakzanisKK (1998) Neurocognitive deficit in schizophrenia: A quantitative review of the evidence. Neuropsychology12: 426–445.
106.
Heresco-LevyU (2002) Amino acid transmitter systems in schizophrenia and other psychotic disorders. In: D’haenenHDen BoerJAWestenbergM. (eds) Biological Psychiatry. London: John Wiley & Sons, pp.587–600.
107.
Heresco-LevyU (2005) Glutamatergic neurotransmission modulators as emerging new drugs for schizophrenia. Expert Opin Emerg Drugs10: 827–844.
108.
Heresco-LevyUJavittDCEbsteinR. (2005) D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia. Biol Psychiatry57: 5775–5785.
109.
HoBCMilevPO’LearyDS. (2006) Cognitive and magnetic resonance imaging brain morphometric correlates of brain-derived neurotrophic factor Val66Met gene polymorphism in patients with schizophrenia and healthy volunteers. Arch Gen Psychiatry63: 731–740.
110.
HoBCAndreasenNCDawsonJD. (2007) Association between brain-derived neurotrophic factor Val66Met gene polymorphism and progressive brain volume changes in schizophrenia. Am J Psychiatry164: 1890–1899.
111.
HogartyGEFlesherSUlrichR. (2004) Cognitive enhancement therapy for schizophrenia: effects of a 2-year randomized trial on cognition and behavior. Arch Gen Psychiatry61: 866–876.
112.
HowardAKThorntonAEAltmanS. (2002) Donepezil for memory dysfunction in schizophrenia. J Psychopharmacol16: 267–270.
113.
HughesCKumariVSoniW. (2003) Longitudinal study of symptoms and cognitive function in chronic schizophrenia. Schizophr Res59: 137–146.
114.
International Schizophrenia Consortium (2008) Rare chromosomal deletions and duplications increase risk of schizophrenia. Nature455: 237–241.
115.
JaskiwGEPopliAP (2004) A meta-analysis of the response to chronic L-dopa in patients with schizophrenia: Therapeutic and heuristic implications. Psychopharmacology171: 365–374.
116.
JonesPRodgersBMurrayR. (1994) Child development risk factors for adult schizophrenia in the British 1946 birth cohort. Lancet344:1398–1402.
117.
KantrowitzJTJavittDC (2010) N-methyl-d-aspartate (NMDA)receptor dysfunction or dysregulation: The final common pathway on the road to schizophrenia?Brain Res Bull83: 108–121.
118.
KantrowitzJTMalhotraAKCornblattB. (2010) High dose D-serine in the treatment of schizophrenia. Schizophr Res121:125–130.
119.
KeefeRSSilvaSGPerkinsDO. (1999) The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: A review and meta-analysis. Schizophr Bull25: 201–222.
120.
KeefeRSSeidmanLJChristensenBK. (2004) Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: A randomized, double-blind trial of olanzapine versus low doses of haloperidol. Am J Psychiatry. 161: 985–995.
121.
KeefeRSYoungCARockSL.; HGGN Study Group (2006) One-year double-blind study of the neurocognitive efficacy of olanzapine, risperidone, and haloperidol in schizophrenia. Schizophr Res81: 1–15.
122.
KeefeRSSweeneyJAGuH. (2007a) Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: A randomized, double-blind 52-week comparison. Am J Psychiatry164: 1061–1071.
123.
KeefeRSBilderRMDavis. (2007b) Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch Gen Psychiatry64: 633–647.
124.
KeefeRSMalhotraAKMeltzerHY. (2008) Efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder: significant placebo/practice effects in a 12-week, randomized, double-blind, placebo-controlled trial. Neuropsychopharmacology33: 1217–1228.
125.
KeefeRSFoxKHHarveyPD. (2011) Characteristic of the MATRICS Consensus Cognitive Battery in a 29-site antipsychotic schizophrenia clinical trial. Schizophr Res125: 161–168.
126.
KegelesLSSlifsteinMXuX. (2010) Striatal and extrastriatal dopamine D2/D3 receptors in schizophrenia evaluated with [18F]fallypride positron emission tomography. Biol Psychiatry68: 634–641.
127.
KellyDGoldbergRWilsonD. (1993) Confirmation that the velo-cardio-facial syndrome is associated with haploinsufficiency of genes at chromosome 22q11. Am J Med Genet45: 308–312.
128.
KellyDLBuchananRWBoggsDL. (2009) A randomized double-blind trial of atomoxetine for cognitive impairments in 32 people with schizophrenia. J Clin Psychiatry70: 518–525.
129.
KerwinRW (1994) The new atypical antipsychotics. A lack of extrapyramidal side-effects and new routes in schizophrenia research. Br J Psychiatry164: 141–148.
130.
KingDJ (1990) The effect of neuroleptics on cognitive and psychomotor function. Br J Psychiatry157: 799–811.
131.
KingDJ (1994) Psychomotor impairment and cognitive disturbances induced by neuroleptics. Acta Psychiatr Scand Suppl380: 53–58.
132.
KircherTKrugAMarkovV. (2009) Genetic variation in the schizophrenia-risk gene neuregulin 1 correlates with brain activation and impaired speech production in a verbal fluency task in healthy individuals. Hum Brain Mapp30: 3406–3416.
133.
KirovGGumusDChenW. (2008) Comparative genome hybridization suggests a role for NRXN1 and APBA2 in schizophrenia. Hum Mol Genet17: 458–465.
134.
KrabbendamLAlemanA (2003) Cognitive rehabilitation in schizophrenia: A quantitative analysis of controlled studies. Psychopharmacology (Berl)169: 376–382.
135.
KraepelinE (1987) Dementia praecox. In: CuttingJShepardM (eds). The Clinical Roots of the Schizophrenia Concept. Cambridge: Cambridge University Press, pp.13–24.
136.
KremenWSSeidmanLJFaraoneSV. (2001) Intelligence quotient and neuropsychological profiles in patients with schizophrenia and in normal volunteers. Biol Psychiatry50: 453–462.
137.
KrugAMarkovVKrachS. (2010) The effect of Neuregulin 1 on neural correlates of episodic memory encoding and retrieval. Neuroimage53: 985–991.
138.
KrystalJHKarperLPSeibylJP. (1994) Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry51: 199–214.
139.
KumariVPostmaP (2005) Nicotine use in schizophrenia: the self medication hypotheses. Neurosci Biobehav Rev29: 1021–1034.
140.
KumariVZachariahEGaleaA. (2003) Effects of acute procyclidine administration on prepulse inhibition of the startle response in schizophrenia: A double-blind, placebo-controlled study. J Psychopharmacology17: 89–95.
141.
KumariVAasenIffytcheD. (2006) Neural correlates of adjunctive rivastigmine treatment to antipsychotics in schizophrenia: A randomized, placebo-controlled, double-blind fMRI study. Neuroimage29: 545–556.
142.
KumariVPetersERFannonD. (2009) Dorsolateral prefrontal cortex activity predicts responsiveness to cognitive-behavioral therapy in schizophrenia. Biol Psychiatry66: 594–602.
143.
KurtzMMMobergPJGurRC. (2001) Approaches to cognitive remediation of neuropsychological deficits in schizophrenia: a review and meta-analysis. Neuropsychol Rev11: 197–210.
144.
KurtzMMWexlerBEFujimotoM. (2008) Symptoms versus neurocognition as predictors of change in life skills in schizophrenia after outpatient rehabilitation. Schizophr Res102: 303–311.
145.
LachmanHMPapolosDFSaitoT. (1996) Human catechol-O-methyltransferase pharmacogenetics: Description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics6: 243–250.
146.
LahtiACWeilerMAMichaelidisT. (2001) Effects of ketamine in normal and schizophrenic volunteers. Neuropsychopharmacology25: 455–467.
147.
LawsKR (1999) A meta-analytic review of Wisconsin Card Sort studies in schizophrenia: general intellectual deficit in disguise?Cogn Neuropsychiatry4: 1–30.
148.
LecardeurLStipEGiguereM. (2009) Effects of cognitive remediation therapies on psychotic symptoms and cognitive complaints in patients with schizophrenia and related disorders: A randomized study. Schizophr Res111: 153–158.
149.
LeeJParkS (2005) Working memory impairments in schizophrenia: A meta-analysis. J Abnorm Psychol114: 599–611.
150.
LeeSWLeeJGLeeBJ. (2007) A 12-week, double-blind, placebo-controlled trial of galantamine adjunctive treatment to conventional antipsychotics for the cognitive impairments in chronic schizophrenia. Int Clin Psychopharmacol22: 63–68.
151.
LeesonPDIversenLL (1994) The glycine site on the NMDA receptor: Structure–activity relationships and therapeutic potential. J Med Chem37: 4053–4067.
152.
LehmanAFCarpenterWTJrGoldmanHH. (1995) Treatment outcomes in schizophrenia: Implications for practice, policy, and research. Schizophr Bull21: 669–675.
153.
LenziAMaltintiEPoggiE. (2003) Effects of rivastigmine on cognitive function and quality of life in patients with schizophrenia. Clin Neuropharmacol26: 317–321.
154.
LeuchtSCorvesCArbterD. (2009) Second-generation versus first-generation antipsychotic drugs for schizophrenia: A meta-analysis. Lancet373: 31–41.
155.
LevinEDRezvaniAH (2000) Development of nicotinic drug therapy for cognitive disorders. Eur J Pharmacol393: 141–146.
156.
LewisDAVolkDWHashimotoT (2004) Selective alterations in prefrontal cortical GABA neurotransmission in schizophrenia: a novel target for the treatment of working memory dysfunction. Psychopharmacology174: 143–150.
157.
LewisDAChoRYCarterCS. (2008) Subunit-selective modulation of GABA type A receptor neurotransmission and cognition in schizophrenia. Am J Psychiatry165: 1585–1593.
158.
LiCS (2004) Do schizophrenia patients make more perseverative than non-perseverative errors on the Wisconsin Card Sorting Test? A meta-analytic study. Psychiatry Res129: 179–190.
159.
LiTZhangFLiuX. (2005) Identifying potential risk haplotypes for schizophrenia at the DTNBP1 locus in Han Chinese and Scottish populations. Mol Psychiatry10: 1037–1044.
160.
LindenmayerJPKhanAIskanderA. (2007) A randomized controlled trial of olanzapine versus haloperidol in the treatment of primary negative symptoms and neurocognitive deficits in schizophrenia. J Clin Psychiatry68: 368–379.
161.
LindenmayerJPMcGurkSRMueserKT. (2008) A randomized controlled trial of cognitive remediation among inpatients with persistent mental illness. Psychiatr Serv59: 241–247.
162.
LiuLWongTPPozzaMF. (2004) Role of NMDA receptor subtypes in governing the direction of hippocampal synaptic plasticity. Science304: 1021–1024.
163.
McCarthySEMakarovVKirovG. (2009) Microduplications of 16p11.2 are associated with schizophrenia. Nat Genet41: 1223-1227.
164.
MacEwanGWEhmannTSKhanbhaiI. (2001) Donepezil in schizophrenia – is it helpful? An experimental design case study. Acta Psychiatr Scand104: 469–472.
165.
McGrathJJ (2007) The surprisingly rich contours of schizophrenia epidemiology. Arch Gen Psychiatry64: 14–16.
166.
McGurkSRMueserKTPascarisA (2005) Cognitive training and supported employment for persons with severe mental illness: One-year results from a randomized controlled trial. Schizophr Bull31: 898–909.
167.
McGurkSRMueserKTFeldmanK. (2007) Cognitive training for supported employment: 2–3 year outcomes of a randomized controlled trial. Am J Psychiatry164: 437–441.
168.
McNabFVarroneAFardeL. (2009) Changes in cortical dopamine D1 receptor binding associated with cognitive training. Science323: 800–802.
169.
MaelickeASamochockiMJostockR. (2001) Allosteric sensitization of nicotinic receptors by galantamine, a new treatment strategy for Alzheimer’s disease. Biol Psychiatry49: 279–288.
170.
MalhotraAKPinalsDAWeingartnerH (1996) NMDA receptor function and human cognition: The effects of ketamine in healthy volunteers. Neuropsychopharmacology14: 301–307.
171.
MalhotraAKKestlerLJMazzantiC. (2002) A functional polymorphism in the COMT gene and performance on a test of prefrontal cognition. Am J Psychiatry159: 652–654.
172.
MandelRJChenADConnorDJ. (1989) Continuous physostigmine infusion in rats with excitotoxic lesions of the nucleus basalis magnocellularis: Effects on performance in the water maze task and cortical cholinergic markers. J Pharmacol Exp Ther251: 612–619.
173.
MarkovVKrugAKrachS. (2009) Genetic variation in schizophrenia-risk-gene dysbindin 1 modulates brain activation in anterior cingulate cortex and right temporal gyrus during language production in healthy individuals. Neuroimage47: 2016–2022.
174.
MartinLFKemWRFreedmanR (2004) Alpha-7 nicotinic receptor agonists: Potential new candidates for the treatment of schizophrenia. Psychopharmacology174: 54–64.
175.
MattayVSGoldbergTEFeraF. (2003) Catechol O-methyltransferase val158-met genotype and individual variation in the brain response to amphetamine. Proc Natl Acad Sci U S A100: 6186–6191.
176.
MaziadeMBissonnetteLRouillardE. (1997) 6p24–2 region and major psychoses in the Eastern Quebec population. Le Groupe IREP. Am J Med Genet74: 311–318.
177.
MechelliAPrataDPFuCH. (2008) The effects of neuregulin1 on brain function in controls and patients with schizophrenia and bipolar disorder. Neuroimage42: 817–826.
178.
MedaliaARevheimNCaseyM (2000) Remediation of memory disorders in schizophrenia. Psychol Med30: 1451–1459.
179.
MeltzerHYRabinowitzJLeeMA. (1997) Age at onset and gender of schizophrenic patients in relation to neuroleptic resistance. Am J Psychiatry154: 475–482.
180.
MenziesLOoiCKamathS. (2007) Effects of gamma-aminobutyric acid modulating drugs on working memory and brain function in patients with schizophrenia. Arch Gen Psychiatry64: 156–167.
181.
MillanMJ (2005) N-Methyl-D-aspartate receptors as a target for improved antipsychotic agents: Novel insights and clinical perspectives. Psychopharmacology179: 30–53.
182.
MisharaALGoldbergTE (2004) A meta-analysis and critical review of the effects of conventional neuroleptic treatment on cognition in schizophrenia: opening a closed book. Biol Psychiatry55: 1013–1022.
183.
MoghaddamB (2003) Bringing order to the glutamate chaos in schizophrenia. Neuron40: 881–884.
184.
MojtabaiRBrometEJHarveyPD. (2000) Neuropsychological differences between first-admission schizophrenia and psychotic affective disorders. Am J Psychiatry157: 1453–1460.
185.
MondelliVCattaneoAMurriMB. (2011) Stress and inflammation reduce brain-derived neurotrophic factor expression in first-episode psychosis: A pathway to smaller hippocampal volume. J Clin Psychiatry72: 1677–1684.
186.
MoriKYamashitaHNagaoM. (2002) Effects of anticholinergic drug withdrawal on memory, regional cerebral blood flow and extrapyramidal side effects in schizophrenic patients. Pharmacopsychiatry35: 6–11.
187.
MoritzSWoodwardTS (2007) Metacognitive training in schizophrenia: from basic research to knowledge translation and intervention. Curr Opin Psychiatry20: 619–625.
188.
MuQJohnsonKMorganPS. (2007) A single 20 mg dose of the full D1 dopamine agonist dihydrexidine (DAR-0100) increases prefrontal perfusion in schizophrenia. Schizophr Res94: 332–341.
189.
MühleisenTWBasmanavFBForstnerAJ. (2011) Resequencing and follow-up of neurexin 1 (NRXN1) in schizophrenia patients. Schizophr Res127: 35–40.
190.
MurrayCJLopezAD (eds) (1996) The Global Burden of Disease: A Comprehensive Assessment of Mortality and Disability from Diseases, Injuries and Risk Factors in 1990 and Projected to 2020. Boston: Harvard School of Public Health, 990pp.
191.
NeedACKeefeRSGeD. (2009) Pharmacogenetics of antipsychotic response in the CATIE trial: A candidate gene analysis. Eur J Hum Genet17: 946–957.
192.
NewhousePAKeltonM (2000) Clinical aspects of nicotinic agents: Therapeutic applications in central nervous system disorders. In: ClementiFFornasariDGottiC (eds) Neuronal Nicotinic Receptors. Experimental Pharmacology, vol. 14, Berlin: Springer, pp.779–812.
193.
NiendamTABeardenCEJohnsonJK. (2006) Neurocognitive performance and functional disability in the psychosis prodrome. Schizophr Res84: 100–111.
194.
NumakawaTYagasakiYIshimotoT. (2004) Evidence of novel neuronal functions of dysbindin, a susceptibility gene for schizophrenia. Hum Mol Genet13: 2699–2708.
195.
OlesenPJWesterbergHKlingbergT (2004) Increased prefrontal and parietal activity after training of working memory. Nat Neurosci7: 75–79.
196.
OusleyORockersKDellML. (2007) A review of neuro-cognitive and behavioral profiles associated with 22q11 deletion syndrome: implications for clinical evaluation and treatment. Curr Psychiatry Rep9: 148–158.
197.
PalmerBWHeatonRKPaulsenJS. (1997) Is it possible to be schizophrenic yet neuropsychologically normal?Neuropsychology11: 437–446.
198.
PardoPJKnesevichMAVoglerGP. (2000) Genetic and state variables of neurocognitive dysfunction in schizophrenia: A twin study. Schizophr Bull26: 459–477.
199.
PatelNHVyasNSPuriBK. (2010) Positron emission tomography in schizophrenia: A new perspective. J Nucl Med51: 511–520.
200.
PatilSTZhangLMartenyiF. (2007) Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: A randomized Phase 2 clinical trial. Nat Med13: 1102–1107.
201.
PetrovskyNQuednowBBEttingerU. (2010) Sensorimotor gating is associated with CHRNA3 polymorphisms in schizophrenia and healthy volunteers. Neuropsychopharmacology35:1429–1439.
202.
PillingSBebbingtonPKuipersE. (2002) Psychological treatments in schizophrenia: I. Meta-analysis of family intervention and cognitive behaviour therapy. Psychol Med32: 763–782.
203.
PirildarSGönülASTaneliF. (2004) Low serum levels of brain-derived neurotrophic factor in patients with schizophrenia do not elevate after antipsychotic treatment. Prog Neuropsychopharmacol Biol Psychiatry28: 709–713.
204.
PooMM (2001) Neurotrophins as synaptic modulators. Nat Rev Neurosci2: 24–32.
205.
PosthumaDLucianoMGeusEJ. (2005) A genomewide scan for intelligence identifies quantitative trait loci on 2q and 6p. Am J Hum Genet77: 318–326.
206.
PowchikPDavidsonMHaroutunianV. (1998) Postmortem studies in schizophrenia. Schizophr Bull24: 325–341.
207.
RabinowitzJLevineSZHaimR. (2007) The course of schizophrenia: Progressive deterioration, amelioration or both?Schizophr Res91: 254–258.
208.
RaznahanALeeYLongR. (2011) Common functional polymorphism of DISC1 and cortical maturation in typically developing children and adolescents. Mol Psychiatry16: 917–926.
209.
ReichenbergAHarveyPD (2007) Neuropsychological impairments in schizophrenia: Integration of performance-based and brain imaging findings. Psychol Bull133: 833–858.
210.
RischSCMcGurkSHornerMD. (2001) A double-blind placebo-controlled case study of the use of donepezil to improve cognition in a schizoaffective disorder patient: functional MRI correlates. Neurocase7: 105–110.
211.
RitsnerMSBlumenkrantzH (2007) Predicting domain-specific insight of schizophrenia patients from symptomatology, multiple neurocognitive functions, and personality related traits. Psychiatry Res149: 59–69.
212.
RizosENRontosILaskosE. (2008) Investigation of serum BDNF levels in drug-naive patients with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry32: 1308–1311.
213.
RosaAPeraltaVCuestaMJ. (2004) New evidence of association between COMT gene and prefrontal neurocognitive function in healthy individuals from sibling pairs discordant for psychosis. Am J Psychiatry161: 1110–1112.
214.
RoussosPGiakoumakiSGAdamakiE. (2011) The influence of schizophrenia-related neuregulin-1 polymorphisms on sensorimotor gating in healthy males. Biol Psychiatry69: 479–486.
215.
SamochockiMZerlinMJostockR. (2000) Galantamine is an allosterically potentiating ligand of the human alpha4/beta2 nAChR. Acta Neurol Scand Suppl176: 68–73.
216.
SamochockiMHöffleAFehrenbacherA. (2003) Galantamine is an allosterically potentiating ligand of neuronal nicotinic but not of muscarinic acetylcholine receptors. J Pharmacol Exp Ther305: 1024–1036.
217.
SavitzJSolmsMRamesarR (2006) The molecular genetics of cognition: Dopamine, COMT and BDNF. Genes Brain Behav5: 311–328.
218.
SchubertMHYoungKAHicksPB (2006) Galantamine improves cognition in schizophrenic patients stabilized on risperidone. Biol Psychiatry60: 530–533.
219.
SchwabSGKnappMMondabonS. (2003) Support for association of schizophrenia with genetic variation in the 6p22.3 gene, dysbindin, in sib-pair families with linkage and in an additional sample of triad families. Am J Hum Genet72: 185–190.
220.
SharmaT (1999) Cognitive effects of conventional and atypical antipsychotics in schizophrenia. Br J Psychiatry Suppl38: 44–51.
221.
SharmaTReedCAasenI. (2006) Cognitive effects of adjunctive 24-weeks Rivastigmine treatment to antipsychotics in schizophrenia: A randomized, placebo-controlled, double-blind investigation. Schizophr Res85: 73–83.
222.
ShiYYHeGZhangZ. (2008) A study of rare structural variants in schizophrenia patients and normal controls from Chinese Han population. Mol Psychiatry13: 911–913.
223.
ShibataHTaniAChikuharaT. (2009) Association study of polymorphisms in the group III metabotropic glutamate receptor genes, GRM4 and GRM7, with schizophrenia. Psychiatry Res167: 88–96.
224.
ShimSSHammondsMDKeeBS (2008) Potentiation of the NMDA receptor in the treatment of schizophrenia: focused on the glycine site. Eur Arch Psychiatry Clin Neurosci258: 16–27.
225.
ShprintzenRJ (2000) Velo-cardio-facial syndrome: A distinctive behavioral phenotype. Ment Retard Dev Disabil Res Rev6: 142–147.
226.
ShprintzenRJGoldbergRBLewinML (1978) A new syndrome involving cleft palate, cardiac anomalies, typical facies, and learning disabilities: Velo-cardio-facial syndrome. Cleft Palate J15: 56–62.
227.
SmithTEHullJWGoodmanM. (1999) The relative influences of symptoms, insight, and neurocognition on social adjustment in schizophrenia and schizoaffective disorder. J Nerv Ment Dis187: 102–108.
228.
SpohnHEStraussME (1989) Relation of neuroleptic and anticholinergic medication to cognitive functions in schizophrenia. J Abnorm Psychol98: 367–380.
229.
StefanssonHSigurdssonESteinthorsdottirV. (2002) Neuregulin 1 and susceptibility to schizophrenia. Am J Hum Genet71: 877–892.
230.
StefanssonHSarginsonJKongA. (2003) Association of neuregulin 1 with schizophrenia confirmed in a Scottish population. Am J Hum Genet72: 83–87.
231.
StefanssonHRujescuDCichonS. (2008) Large recurrent microdeletions associated with schizophrenia. Nature455: 232–236.
232.
StraubREJiangYMacLeanCJ. (2002) Genetic variation in the 6p22.3 gene DTNBP1, the human ortholog of the mouse dysbindin gene, is associated with schizophrenia. Am J Hum Genet71: 337–348.
233.
StraussMEReynoldsKSJayaramG. (1990) Effects of anticholinergic medication on memory in schizophrenia. Schizophr Res3: 127–129.
234.
StryjerRBarFStrousRD. (2002) Donepezil management of schizophrenia with associated dementia. J Clin Psychopharmacol22: 226–229.
235.
SumiyoshiTMatsuiMNoharaS. (2001) Enhancement of cognitive performance in schizophrenia by addition of tandospirone to neuroleptic treatment. Am J Psychiatry158: 1722–1725.
236.
SumiyoshiTParkSJayathilakeK. (2007) Effect of buspirone, a serotonin1A partial agonist, on cognitive function in schizophrenia: A randomized, double-blind, placebo-controlled study. Schizophr Res95: 158–168.
237.
SumiyoshiTBubenikova-ValesovaVHoracekJ. (2008) Serotonin1A receptors in the pathophysiology of schizophrenia: Development of novel cognition-enhancing therapeutics. Adv Ther25: 1037–1056.
238.
Tabarés-SeisdedosRBalanzá-MartínezVSánchez-MorenoJ. (2008) Neurocognitive and clinical predictors of functional outcome in patients with schizophrenia and bipolar I disorder at one-year follow-up. J Affect Disord109: 286–299.
239.
TakahashiTSuzukiMTsunodaM. (2008) Association between the brain-derived neurotrophic factor Val66Met polymorphism and brain morphology in a Japanese sample of schizophrenia and healthy comparisons. Neurosci Lett435: 34–39.
240.
TalkowskiMEKirovGBamneM. (2008) A network of dopaminergic gene variations implicated as risk factors for schizophrenia. Hum Mol Genet17: 747–758.
241.
TangJXZhouJFanJB. (2003) Family-based association study of DTNBP1 in 6p22.3 and schizophrenia. Mol Psychiatry8: 717–718.
242.
TerryAVJrBuccafuscoJJ (2003) The cholinergic hypothesis of age and Alzheimer’s disease-related cognitive deficits: recent challenges and their implications for novel drug development. J Pharmacol Exp Ther306: 821–827.
243.
TosatoSRuggeriMBonettoC. (2007) Association study of dysbindin gene with clinical and outcome measures in a representative cohort of Italian schizophrenic patients. Am J Med Genet B Neuropsychiatr Genet144B: 647–659.
244.
TsaiGYangPChungLC. (1998) D-serine added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry44: 1081–1089.
245.
TsaiGEYangPChungLC. (1999) D-serine added to clozapine for the treatment of schizophrenia. Am J Psychiatry156: 1822–1825.
246.
TsaiSJYuYWChenTJ. (2003) Association study of a functional catechol-O-methyltransferase-gene polymorphism and cognitive function in healthy females. Neurosci Lett338: 123–126
247.
TugalOYaziciKMAnil YağcioğluAE. (2004) A double-blind, placebo controlled, cross-over trial of adjunctive donepezil for cognitive impairment in schizophrenia. Int J Neuropsychopharmacol7: 117–123.
248.
TuominenHJTiihonenJWahlbeckK (2005) Glutamatergic drugs for schizophrenia: A systematic review and meta-analysis. Schizophr Res72: 225–234.
249.
Van den OordEJSullivanPFJiangY. (2003) Identification of a high-risk haplotype for the dystrobrevin binding protein 1 (DTNBP1) gene in the Irish study of high-density schizophrenia families. Mol Psychiatry8: 499–510.
250.
Van PuttenTMarderSR (1987) Behavioural toxicity of antipsychotic drugs. J Clin Psychiatry48: 13–19.
251.
VelliganDIMahurinRKDiamondPL. (1997) The functional significance of symptomatology and cognitive function in schizophrenia. Schizophr Res25: 21–31.
252.
VilellaECostasJSanjuanJ. (2008) Association of schizophrenia with DTNBP1 but not with DAO, DAOA, NRG1 and RGS4 nor their genetic interaction. J Psychiatr Res42: 278–288.
253.
VinogradovSFisherMWarmH. (2009) The cognitive cost of anticholinergic burden: Decreased response to cognitive training in schizophrenia. Am J Psychiatry166: 1055–1062.
254.
VrijenhoekTBuizer-VoskampJEvan der SteltI., Genetic Risk and Outcome in Psychosis (GROUP) Consortium (2008) Recurrent CNVs disrupt three candidate genes in schizophrenia patients. Am J Hum Genet83: 504–510.
255.
VyasNSPuriBK (2012) Evidence for an association between brain-derived neurotrophic factor Val66Met gene polymorphism and general intellectual ability in early-onset schizophrenia. Isr J Psychiatry Relat Sci. In Press.
256.
VyasNSHadjulisMVourdasA. (2007) The Maudsley early onset schizophrenia study. Predictors of psychosocial outcome at 4-year follow-up. Eur Child Adolesc Psychiatry16: 465–470.
257.
VyasNSKumraSPuriBK (2010a) What insights can we gain from studying early-onset schizophrenia? The neurodevelopmental pathway and beyond. Exp Rev Neurother10: 1243–1247.
258.
VyasNSPatelNHNijranKS. (2010b) Can PET/CT imaging advance our understanding of the neurobiology of schizophrenia?Nucl Med Comm31: 91–93.
259.
VyasNSPatelNHNijranKS. (2010c) Insights into schizophrenia using positron emission tomography: Building the evidence and refining the focus. Br J Psychiatry197: 3–4.
260.
VyasNSPatelNHNijranKS. (2011a) The use of positron emission tomography imaging in understanding cognition, genetics and pharmacotherapeutic interventions in schizophrenia. Exp Rev Neurother11: 37–51.
261.
VyasNSPatelNHPuriBK (2011b) Neurobiology and phenotypic expression in early onset schizophrenia. Early Interv Psychiatry5: 3–14.
262.
WalshTMcClellanJMMcCarthySE. (2008) Rare structural variants disrupt multiple genes in neurodevelopmental pathways in schizophrenia. Science320: 539–543.
263.
WeickertCSStraubREMcClintockBW. (2004a) Human dysbindin (DTNBP1) gene expression in normal brain and in schizophrenic prefrontal cortex and midbrain. Arch Gen Psychiatry61: 544–555.
264.
WeickertTWGoldbergTEMisharaA. (2004b) Catechol-O-methyltransferase val108/158met genotype predicts working memory response to antipsychotic medications. Biol Psychiatry56: 677–682.
265.
WeickertCSRothmondDAHydeTM. (2008) Reduced DTNBP1 (dysbindin-1) mRNA in the hippocampal formation of schizophrenia patients. Schizophr Res98: 105–110.
266.
WeinbergerDREganMFBertolinoA. (2001) Prefrontal neurons and the genetics of schizophrenia. Biol Psychiatry50: 825–844.
267.
WhalleyHCBaigBJHallJ. (2010) Effects of the BDNF val66met polymorphism on prefrontal brain function in a population at high genetic risk of schizophrenia. Am J Med Genet B Neuropsychiatr Genet153: 1474–1482.
268.
WilkCMGoldJMMcMahonRP. (2005) No, it is not possible to be schizophrenic yet neuropsychologically normal. Neuropsychology19: 778–786.
269.
WilliamsNMPreeceAMorrisDW. (2004) Identification in 2 independent samples of a novel schizophrenia risk haplotype of the dystrobrevin binding protein gene (DTNBP1). Arch Gen Psychiatry61: 336–344.
270.
WilliamsNMO’DonovanMCOwenMJ (2005) Is the dysbindin gene (DTNBP1) a susceptibility gene for schizophrenia?Schizophr Bull31: 800–805.
271.
WoodwardNDPurdonSEMeltzerHY. (2005) A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int J Neuropsychopharmacol8: 457–472.
272.
WoodwardNDJayathilakeKMeltzerHY (2007) COMT val108/158met genotype cognitive function, and cognitive improvement with clozapine in schizophrenia. Schizophr Res90: 86–96.
273.
World Health Organization (2001) Mental health: New understanding, new hope. World Health report2001. Geneva: World Health Organization.
274.
WykesT (2008) Review: Cognitive remediation improves cognitive functioning in schizophrenia. Evid Based Ment Health11: 117.
275.
WykesTDunnG (1992) Cognitive deficit and the prediction of rehabilitation success in a chronic psychiatric group. Psychol Med22: 389–398.
276.
WykesTReederCCornerJ. (1999) The effects of neurocognitive remediation on executive processing in patients with schizophrenia. Schizophr Bull25: 291–307.
277.
WykesTReederCWilliamsC. (2003) Are the effects of cognitive remediation therapy (CRT) durable? Results from an exploratory trial in schizophrenia. Schizophr Res61: 163–174.
278.
XuBWoodroffeARodriguez-MurilloL. (2009) Elucidating the genetic architecture of familial schizophrenia using rare copy number variant and linkage scans. Proc Natl Acad Sci USA106: 16746–16751.
279.
ZammitSAllebeckPDavidAS. (2004) A longitudinal study of premorbid IQ score and risk of developing schizophrenia, bipolar disorder, severe depression, and other nonaffective psychoses. Arch Gen Psychiatry61: 354–360.
280.
ZuoLLuoXKrystalJH. (2009) The efficacies of clozapine and haloperidol in refractory schizophrenia are related to DTNBP1 variation. Pharmacogenet Genomics19: 437–446.
